Cellbri manufactures automated CGT industrial instruments designed for efficient cell processing in biomanufacturing. Their technology enhances the precision and scalability of cell therapies, addressing the need for reliable and consistent production methods in the growing biotech sector.
Funding
Funding not disclosed
CHFHFounders
Product
Problem
The biomanufacturing of cell and gene therapies (CGTs) requires precise and scalable cell processing methods. Traditional manual or semi-automated techniques often lack the consistency and efficiency needed for large-scale production, hindering the widespread adoption of these therapies.
Solution
Cellbri develops automated CGT industrial instruments designed to enhance the precision and scalability of cell processing in biomanufacturing. Their technology aims to address the critical need for reliable and consistent production methods within the rapidly expanding biotech sector. By automating key steps in cell therapy manufacturing, Cellbri's instruments reduce variability, improve throughput, and lower overall production costs. This enables biomanufacturers to produce cell therapies at a scale and cost that makes them more accessible to patients.
Target Audience
Cellbri's primary customers are biopharmaceutical companies, contract manufacturing organizations (CMOs), and academic research institutions involved in the development and manufacturing of cell and gene therapies.
Features
- Automated cell processing for increased precision and reproducibility
- Scalable design to support large-scale CGT manufacturing
- Integrated process monitoring and control for real-time optimization
- Modular architecture for flexible configuration and customization